Galapagos NV - Product Pipeline Review - 2016

Date: July 13, 2016
Pages: 64
Price:
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G61F48717D3EN
Leaflet:

Download PDF Leaflet

Galapagos NV - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Galapagos NV - Product Pipeline Review - 2016’, provides an overview of the Galapagos NV’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Galapagos NV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the pipeline therapeutic landscape of Galapagos NV
  • The report provides overview of Galapagos NV including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Galapagos NV’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Galapagos NV’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Galapagos NV’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Galapagos NV
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Galapagos NV’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Galapagos NV Snapshot
Galapagos NV Overview
Key Information
Key Facts
Galapagos NV - Research and Development Overview
Key Therapeutic Areas
Galapagos NV - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Galapagos NV - Pipeline Products Glance
Galapagos NV - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Galapagos NV - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Galapagos NV - Drug Profiles
filgotinib
Product Description
Mechanism of Action
R&D Progress

GLPG-1205

Product Description
Mechanism of Action
R&D Progress

GLPG-1690

Product Description
Mechanism of Action
R&D Progress

GLPG-1837

Product Description
Mechanism of Action
R&D Progress

DT-200

Product Description
Mechanism of Action
R&D Progress

GLPG-1972

Product Description
Mechanism of Action
R&D Progress

GLPG-2222

Product Description
Mechanism of Action
R&D Progress

GLPG-2451

Product Description
Mechanism of Action
R&D Progress

MOR-106

Product Description
Mechanism of Action
R&D Progress

GLPG-1492

Product Description
Mechanism of Action
R&D Progress

GLPG-1790

Product Description
Mechanism of Action
R&D Progress

GLPG-1837 + GLPG-2222 + GLPG-2665

Product Description
Mechanism of Action
R&D Progress

GLPG-2534

Product Description
Mechanism of Action
R&D Progress

GLPG-2665

Product Description
Mechanism of Action
R&D Progress

GLPG-2737

Product Description
Mechanism of Action
R&D Progress

GLPG-2851

Product Description
Mechanism of Action
R&D Progress

GLPG-2938

Product Description
Mechanism of Action
R&D Progress
Galapagos NV - Pipeline Analysis
Galapagos NV - Pipeline Products by Target
Galapagos NV - Pipeline Products by Route of Administration
Galapagos NV - Pipeline Products by Molecule Type
Galapagos NV - Pipeline Products by Mechanism of Action
Galapagos NV - Recent Pipeline Updates
Galapagos NV - Dormant Projects
Galapagos NV - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles

GLPG-0187


GLPG-0259


GLPG-1179


GLPG-1205


GLPG-1332


GLPG-1577

Galapagos NV - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Galapagos NV, Key Information
Galapagos NV, Key Facts
Galapagos NV - Pipeline by Indication, 2016
Galapagos NV - Pipeline by Stage of Development, 2016
Galapagos NV - Monotherapy Products in Pipeline, 2016
Galapagos NV - Combination Treatment Modalities in Pipeline, 2016
Galapagos NV - Partnered Products in Pipeline, 2016
Galapagos NV - Partnered Products/ Combination Treatment Modalities, 2016
Galapagos NV - Out-Licensed Products in Pipeline, 2016
Galapagos NV - Out-Licensed Products/ Combination Treatment Modalities, 2016
Galapagos NV - Phase II, 2016
Galapagos NV - Phase I, 2016
Galapagos NV - Preclinical, 2016
Galapagos NV - Discovery, 2016
Galapagos NV - Pipeline by Target, 2016
Galapagos NV - Pipeline by Route of Administration, 2016
Galapagos NV - Pipeline by Molecule Type, 2016
Galapagos NV - Pipeline Products by Mechanism of Action, 2016
Galapagos NV - Recent Pipeline Updates, 2016
Galapagos NV - Dormant Developmental Projects,2016
Galapagos NV - Discontinued Pipeline Products, 2016
Galapagos NV, Subsidiaries

LIST OF FIGURES

Galapagos NV - Pipeline by Top 10 Indication, 2016
Galapagos NV - Pipeline by Stage of Development, 2016
Galapagos NV - Monotherapy Products in Pipeline, 2016
Galapagos NV - Pipeline by Target, 2016
Galapagos NV - Pipeline by Route of Administration, 2016
Galapagos NV - Pipeline by Molecule Type, 2016
Galapagos NV - Pipeline Products by Mechanism of Action, 2016
Skip to top


Ask Your Question

Galapagos NV - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: